Loading...
Neuren Pharmaceuticals Limited
NEU.AX•ASX
Healthcare
Biotechnology
$11.57
$-0.38(-3.18%)
Australian Market opens in 3h 34mNeuren Pharmaceuticals Limited (NEU.AX) AI-Powered Stock Analysis
See how Neuren Pharmaceuticals Limited scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerNeuren Pharmaceuticals Limited (NEU.AX) Stock Overall Grade
Neuren Pharmaceuticals Limited’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Neuren Pharmaceuticals Limited's overall stock rating.
Forecast
BScore
69/100Financial Growth
CScore
40/100Fundamental Growth
AScore
86/100Key Ratios
B+Score
77/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
95/100Analyst Consensus
C+Score
50/100Neuren Pharmaceuticals Limited (NEU.AX) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 69/100 (B), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (86/100, A) highlight its stability, while Key Ratios (77/100, B+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (95/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Neuren Pharmaceuticals Limited stock grade, including financials, comparisons, and forecasts.